Barclays Reinstates Allergen (AGN) at Equalweight
Get access to the best calls on Wall Street with StreetInsider.com's Ratings Insider Elite. Get your Free Trial here.
Barclays reinstated coverage on Allergen (NYSE: AGN) with an Equalweight rating and a price target of $250.00.
Shares of Allergen closed at $213.44 yesterday.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Goldman Sees Execution As Key For Allergan (AGN) In 2017
- Barclays Reacts To Favorable FDA Decision For Jazz Pharmaceuticals (JAZZ)
- SunTrust Robinson Humphrey Starts RPC Inc. (RES) at Buy
Create E-mail Alert Related CategoriesNew Coverage
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!